Study analysis · Proceedings of the National Academy of Sciences of the United States of America · 1995
Estrogen and anti-estrogen both make the estrogen receptor's two halves stick together — but only estrogen turns on genes.
In lab cells, estrogen makes two separate parts of the estrogen receptor team up to switch on genes, while an anti-estrogen lets them touch but not switch genes on.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study was done in cells in a lab, not in people or animals. It shows how a tiny part of a cell works, like figuring out how a key fits a lock. But it doesn't tell us if this matters for human health or disease.
What’s the bottom line?
Scientists studied the estrogen receptor, a protein that turns genes on when estrogen binds. They split the receptor into two parts and put them in cells. The parts could work together only when the real estrogen (17β-estradiol) was present. An antiestrogen let them stick together but did not turn genes on. Mutations that broke either part or estrogen binding stopped the teamwork.
How strong is this study?
The scientists did careful experiments with controls and mutations to test their idea. But because it's only in cells, we don't know if the same thing happens in a real body. Also, they didn't mention if they did things like blinding, which can affect trust.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
19 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control group+15/15
- Sample sizeno sample size reported
- Follow-upno follow-up reported
100 / 100
0 / 100
- P-valuesno p-values reported
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 54 / 100
Probability of being correct
Snapshots of a population at a single point in time, or descriptions of small groups. Can identify correlations and prevalence, but cannot determine cause and effect.
This design cannot establish causation — the findings describe an association, not a cause. In vitro mechanistic study using cell culture; cannot establish causal relationships in humans or clinical outcomes. Findings are limited to molecular mechanisms in the experimental system.
No Conflicts
No conflicts of interest identified
No conflicts identified
No conflict of interest or funding statement present in the provided text. Authors are affiliated with the University of Illinois, Urbana. The study appears to be academic and independently conducted.
Key takeaways
- 01
The two receptor parts interacted and boosted gene activity only with 17β-estradiol.
- 02
Mutations that destroyed AF-1, AF-2, or estrogen binding eliminated the interaction.
- 03
No human outcomes or risk numbers were reported.
- 04
This is a lab-dish mechanism study, so there is no absolute risk, baseline risk, or extra cases per 1,000 people to report.
- 05
It does not measure cancer, hormone therapy outcomes, or any clinical effect.
- 06
The absolute risk or benefit in people was not reported in this study.
Surprising findings
- Antiestrogen promoted the association of AF-1 and AF-2 but did not produce transcriptional synergism.It contradicts the simple model that antiestrogens only prevent receptor activation by blocking estrogen binding. Here, they actively helped the two receptor regions associate, yet genes stayed off.
- Two separate polypeptides corresponding to different ER regions could reassemble into a functional transcription factor in living cells.Most people think a protein must be one continuous chain to work. This shows that modular pieces can find each other and cooperate, at least in this in vitro system.
- No relative or absolute effect sizes, p-values, or confidence intervals were reported for the transcriptional readouts.Modern readers expect quantitative stats, but this 1995 study reports mechanistic presence/absence results rather than effect sizes. That makes it hard to judge the magnitude of the interaction.
Practical takeaways
Don't assume antiestrogens like tamoxifen simply block estrogen from binding. Their effects may depend on how they change receptor shape and which parts of the receptor interact.
This is an in vitro mammalian cell study with no human or animal outcomes. The findings are mechanistic and cannot be directly translated into clinical advice.
low confidenceThink of hormones as activators of DNA segments, not direct causes of body changes. The DNA ultimately determines the outcome.
This is a simplified model from a single in vitro study. Real human biology involves many genes, cell types, and feedback loops.
medium confidenceWhen reading about hormone receptors, look for whether studies report relative vs absolute effects. This study reports no effect sizes at all, so magnitude cannot be judged.
Mechanistic studies often prioritize whether an interaction occurs over how large it is. That's useful for understanding biology but not for estimating risk.
high confidenceWhy this study matters
The estrogen receptor is a two-part machine
The estrogen receptor (ER) is a 66-kDa protein with two activation functions: AF-1 in the amino-terminal region and AF-2 in the carboxyl-terminal, ligand-binding region. When expressed as separate polypeptides in mammalian cells, these two regions can functionally interact — but only in the presence of a ligand such as 17β-estradiol (E2) or an antiestrogen. No relative or absolute effect sizes were reported; this is an in vitro mechanistic study without clinical outcomes.
It shows that a single protein can be split into modules that reassemble, which is a fundamental insight into how hormones control genes.
Antiestrogen lets the parts meet but not work
The interaction between AF-1 and AF-2 was transcriptionally productive only when E2 was bound. Antiestrogen binding promoted association of the two regions but did not lead to transcriptional synergism. This means the same receptor can assemble differently depending on which ligand is attached.
Most people assume antiestrogens simply block estrogen from binding. This study suggests they can still change the receptor's shape and promote part-to-part contact, yet fail to switch genes on.
Mutations break the teamwork
Point or deletion mutations that destroy AF-1 activity, AF-2 activity, or E2 binding eliminated the ligand-dependent interaction and transcriptional synergism. All three pieces — AF-1, AF-2, and the estrogen-binding site — are required for the receptor to work.
It's a clean genetic proof that each part is necessary, which helps explain why some receptor mutations cause disease or drug resistance.
Estrogen changes the receptor's shape
The study suggests that E2 binding alters ER conformation to promote association of the amino- and carboxyl-terminal regions, leading to transcriptional synergism between AF-1 and AF-2. This provides a mechanistic explanation for how estrogen converts the receptor into a fully active transcription factor.
It answers a core question: how does a hormone outside the DNA actually change gene activity? The answer is shape-shifting, not direct DNA binding by the hormone itself.
Modular design is evolutionarily conserved
The productive reassembly of two separate ER polypeptides demonstrates that nuclear hormone receptors have a modular structural and functional organization, with separable domains that can reconstitute a complete transcription factor. This supports the idea that this receptor family is built from mix-and-match modules.
It means lessons from the estrogen receptor may apply to many other hormone receptors, from testosterone to vitamin D.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists studied the estrogen receptor, a protein that turns genes on when estrogen binds. They split the receptor into two parts and put them in cells. The parts could work together only when the real estrogen (17β-estradiol) was present. An antiestrogen let them stick together but did not turn genes on. Mutations that broke either part or estrogen binding stopped the teamwork.
Research results
The two receptor parts interacted and boosted gene activity only with 17β-estradiol. Mutations that destroyed AF-1, AF-2, or estrogen binding eliminated the interaction. No human outcomes or risk numbers were reported.
What this means - more context
This is a lab-dish mechanism study, so there is no absolute risk, baseline risk, or extra cases per 1,000 people to report. It does not measure cancer, hormone therapy outcomes, or any clinical effect. The absolute risk or benefit in people was not reported in this study.
To test whether the amino-terminal activation function (AF-1) and carboxyl-terminal ligand-binding activation function (AF-2) of the estrogen receptor (ER) can functionally interact when expressed as separate polypeptides in mammalian cells, and to determine the role of ligand binding in that interaction.
In mammalian cell-based assays, separate ER polypeptides containing AF-1 and AF-2 functionally interacted in response to 17β-estradiol (E2) and antiestrogen binding. The interaction was transcriptionally productive only with E2; antiestrogen promoted association but not transcriptional synergism. Point or deletion mutations destroying AF-1 activity, AF-2 activity, or E2 binding eliminated the interaction. No relative or absolute effect sizes, p-values, confidence intervals, or clinical risk estimates were reported. The study is not retracted and has no corrections reported.
Methods Used
Mammalian cell-based assays using separate ER polypeptide constructs, ligand treatments (17β-estradiol and antiestrogen), point and deletion mutants, and transcriptional readouts. No sample size, randomization, blinding, or follow-up duration was specified.
Main Finding
E2 binding alters ER conformation to promote association of the amino- and carboxyl-terminal regions, leading to transcriptional synergism between AF-1 and AF-2. This ligand-dependent interaction is transcriptionally productive only with E2 and is eliminated by mutations that destroy AF-1 activity, AF-2 activity, or E2 binding. No relative or absolute effect sizes were reported, and no absolute risk framing is applicable because this is an in vitro mechanistic study without clinical outcomes.
Confidence Level
Moderate. The mechanistic conclusions are supported by in vitro mammalian cell assays with mutant controls, but reliability is limited by the absence of quantitative effect sizes, statistical reporting, and any human or animal outcome data. No retraction or corrections reported.
Study Flags
Red Flags
- •In vitro mammalian cell assays only; no human or animal outcomes measured
- •No effect sizes, p-values, confidence intervals, or absolute risk reported
- •Mechanistic findings cannot be directly translated into clinical risk or benefit
Surprising Findings
Antiestrogen promoted the association of AF-1 and AF-2 but did not produce transcriptional synergism.
It contradicts the simple model that antiestrogens only prevent receptor activation by blocking estrogen binding. Here, they actively helped the two receptor regions associate, yet genes stayed off.
Practical Takeaways
Don't assume antiestrogens like tamoxifen simply block estrogen from binding. Their effects may depend on how they change receptor shape and which parts of the receptor interact.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 54 / 100
Probability of being correct
Snapshots of a population at a single point in time, or descriptions of small groups. Can identify correlations and prevalence, but cannot determine cause and effect.
In Vitro Cross-Sectional
Subject
Lower probability
on the GRADE evidence scale
This study was done in cells in a lab, not in people or animals. It shows how a tiny part of a cell works, like figuring out how a key fits a lock. But it doesn't tell us if this matters for human health or disease.
The study has a COI section but no disclosure was found. A small penalty has been applied.
Strengths
- Controlled experimental system with mutations and ligand treatments
- Use of point and deletion mutations to test specificity
- Demonstrates functional interaction with controls
Weaknesses
- In vitro only, no in vivo validation
- No sample size or statistical details in excerpt
- Blinding not reported
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists studied the estrogen receptor, a protein that turns genes on when estrogen binds. They split the receptor into two parts and put them in cells. The parts could work together only when the real estrogen (17β-estradiol) was present. An antiestrogen let them stick together but did not turn genes on. Mutations that broke either part or estrogen binding stopped the teamwork.
Research results
The two receptor parts interacted and boosted gene activity only with 17β-estradiol. Mutations that destroyed AF-1, AF-2, or estrogen binding eliminated the interaction. No human outcomes or risk numbers were reported.
What this means - more context
This is a lab-dish mechanism study, so there is no absolute risk, baseline risk, or extra cases per 1,000 people to report. It does not measure cancer, hormone therapy outcomes, or any clinical effect. The absolute risk or benefit in people was not reported in this study.
To test whether the amino-terminal activation function (AF-1) and carboxyl-terminal ligand-binding activation function (AF-2) of the estrogen receptor (ER) can functionally interact when expressed as separate polypeptides in mammalian cells, and to determine the role of ligand binding in that interaction.
In mammalian cell-based assays, separate ER polypeptides containing AF-1 and AF-2 functionally interacted in response to 17β-estradiol (E2) and antiestrogen binding. The interaction was transcriptionally productive only with E2; antiestrogen promoted association but not transcriptional synergism. Point or deletion mutations destroying AF-1 activity, AF-2 activity, or E2 binding eliminated the interaction. No relative or absolute effect sizes, p-values, confidence intervals, or clinical risk estimates were reported. The study is not retracted and has no corrections reported.
Methods Used
Mammalian cell-based assays using separate ER polypeptide constructs, ligand treatments (17β-estradiol and antiestrogen), point and deletion mutants, and transcriptional readouts. No sample size, randomization, blinding, or follow-up duration was specified.
Main Finding
E2 binding alters ER conformation to promote association of the amino- and carboxyl-terminal regions, leading to transcriptional synergism between AF-1 and AF-2. This ligand-dependent interaction is transcriptionally productive only with E2 and is eliminated by mutations that destroy AF-1 activity, AF-2 activity, or E2 binding. No relative or absolute effect sizes were reported, and no absolute risk framing is applicable because this is an in vitro mechanistic study without clinical outcomes.
Confidence Level
Moderate. The mechanistic conclusions are supported by in vitro mammalian cell assays with mutant controls, but reliability is limited by the absence of quantitative effect sizes, statistical reporting, and any human or animal outcome data. No retraction or corrections reported.
Study Flags
Red Flags
- •In vitro mammalian cell assays only; no human or animal outcomes measured
- •No effect sizes, p-values, confidence intervals, or absolute risk reported
- •Mechanistic findings cannot be directly translated into clinical risk or benefit
Surprising Findings
Antiestrogen promoted the association of AF-1 and AF-2 but did not produce transcriptional synergism.
It contradicts the simple model that antiestrogens only prevent receptor activation by blocking estrogen binding. Here, they actively helped the two receptor regions associate, yet genes stayed off.
Practical Takeaways
Don't assume antiestrogens like tamoxifen simply block estrogen from binding. Their effects may depend on how they change receptor shape and which parts of the receptor interact.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 54 / 100
Probability of being correct
Snapshots of a population at a single point in time, or descriptions of small groups. Can identify correlations and prevalence, but cannot determine cause and effect.
In Vitro Cross-Sectional
Subject
Lower probability
on the GRADE evidence scale
This study was done in cells in a lab, not in people or animals. It shows how a tiny part of a cell works, like figuring out how a key fits a lock. But it doesn't tell us if this matters for human health or disease.
The study has a COI section but no disclosure was found. A small penalty has been applied.
Strengths
- Controlled experimental system with mutations and ligand treatments
- Use of point and deletion mutations to test specificity
- Demonstrates functional interaction with controls
Weaknesses
- In vitro only, no in vivo validation
- No sample size or statistical details in excerpt
- Blinding not reported
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The scientists did careful experiments with controls and mutations to test their idea. But because it's only in cells, we don't know if the same thing happens in a real body. Also, they didn't mention if they did things like blinding, which can affect trust.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
19 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control group+15/15
- Sample sizeno sample size reported
- Follow-upno follow-up reported
100 / 100
0 / 100
- P-valuesno p-values reported
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 54 / 100
Probability of being correct
Snapshots of a population at a single point in time, or descriptions of small groups. Can identify correlations and prevalence, but cannot determine cause and effect.
This design cannot establish causation — the findings describe an association, not a cause. In vitro mechanistic study using cell culture; cannot establish causal relationships in humans or clinical outcomes. Findings are limited to molecular mechanisms in the experimental system.
No Conflicts
No conflicts of interest identified
No conflicts identified
No conflict of interest or funding statement present in the provided text. Authors are affiliated with the University of Illinois, Urbana. The study appears to be academic and independently conducted.
Standing
The people behind it
The researchers who wrote the study this analysis is built on.
Authored by
3 researchersIf this is your work, this is how we attribute it on Fit Body Science. W. Lee Kraus is listed as the lead author.